Last reviewed 2026-05-28 · How we verify

Sacuitril

University Hospital, Basel, Switzerland · Phase 1 active Small molecule ✓ Verified May 2026

Sacuitril is a Small molecule drug developed by University Hospital, Basel, Switzerland. It is currently in Phase 1 development. Also known as: Entresto.

Sacuitril is a medication used in combination with 177Lu-PP-F11N for the treatment of metastatic medullary thyroid cancer. The exact mechanism of Sacuitril is not specified in the provided facts, but it is being studied in combination with 177Lu-PP-F11N for receptor targeted therapy and imaging of metastatic thyroid cancer.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Sacuitril
Also known as	Entresto
Sponsor	University Hospital, Basel, Switzerland
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer (EARLY_PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Sacuitril CI brief — competitive landscape report
Sacuitril updates RSS · CI watch RSS
University Hospital, Basel, Switzerland portfolio CI

Frequently asked questions about Sacuitril

What is Sacuitril?

Sacuitril is a Small molecule drug developed by University Hospital, Basel, Switzerland.

Who makes Sacuitril?

Sacuitril is developed by University Hospital, Basel, Switzerland (see full University Hospital, Basel, Switzerland pipeline at /company/university-hospital-basel-switzerland).

Is Sacuitril also known as anything else?

Sacuitril is also known as Entresto.

What development phase is Sacuitril in?

Sacuitril is in Phase 1.

Manufacturer: University Hospital, Basel, Switzerland — full pipeline
Therapeutic area: All drugs in Other
Also known as: Entresto

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing